September 2, 2020
Less than a week after its launch on August 26, Mitsubishi Tanabe Pharma’s new hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor Vafseo (vadadustat) is already facing shortages due to stronger-than-expected demand, forcing the company to curb shipments for one of its...read more